Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse
17.3.2025 23:00:00 CET | Business Wire | Press release
Queensland’s major airport pioneers data consolidation in the cloud to drive operational efficiency
Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/
Brisbane Airport
Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis.
Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand.
“Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to consolidate and accelerate digitization, leading to improved decision-making and operational performance.
"Our data will be a crucial asset in driving efficiency and elevating the traveler experience at Brisbane Airport."
Ryan Both, Brisbane Airport Executive General Manager Aviation said: “Accessing Cirium’s schedules data through Cirium Sky Warehouse enables advanced automation, marking a critical step in Brisbane Airport’s digital transformation project.”
“The schedules data plays a critical role in creating and executing more accurate flight schedules, planning for future events and fluctuations in air traffic, gaining more comprehensive insights, and making decisions for business growth. This will lead to numerous improvements around efficiency, sustainability and passenger experience.”
“Embracing a cloud-based data integration approach also means we will significantly reduce the time spent internally on data and ultimately drive cost efficiencies.”
Brisbane Airport is currently undergoing a transformation program known as Future BNE, which includes 150 projects over a 10-year period, focusing on upgrades to the airport’s domestic and international terminals, as well as planning for a third terminal, ahead of the city hosting the 2032 Olympics.
This first phase modernization will support an improved experience for the almost 25 million passengers currently passing through its terminals and the additional 10 million expected over the coming decade.
The Cirium Sky Warehouse delivers the highest quality aviation data and analytics in one accessible data cloud, aligning seamlessly with Brisbane Airport’s digital transformation objectives. While the airport will initially leverage schedules data, a wealth of other data can be accessed and integrated from Cirium Sky Warehouse including flight, traffic, fleet, fares, weather, and CO2 emissions.
By leveraging the power of Cirium’s data cloud, Brisbane Airport joins global major airlines, fuel supply companies, aviation financiers, and more in enhancing its planning, operational efficiency and growth opportunities.
Notes to editors
To find out more about the Cirium Sky Warehouse, click here.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth. Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. For further information please follow Cirium on LinkedIn or visit cirium.com.
About Brisbane Airport
BNE is the third-largest airport in Australia by passenger numbers, with 24 million passengers travelling through the airport annually. BNE contributes $4.7 billion GDP annually, with 1 in 70 Queensland jobs enabled by BNE and benefits provided range of key industries such as tourism, resources and international education. BNE is the largest airport in Australia by land size, covering 2,700 hectares of land used for aviation, property development and consumer businesses, which employ over 20,000 people. In 2025 it celebrates 100 years of operation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317052819/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom